{"name":"Inflammasome Therapeutics","slug":"inflammasome-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Kamlanoflast","genericName":"Kamlanoflast","slug":"kamlanoflast","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Kamlanoflast","genericName":"Kamlanoflast","slug":"kamlanoflast","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPb2pINHNSM2VIVlM5bWlablVWOTk4a1pCWV8wUURFZjEtLTVCR3N5T3BWRllYNVgwRXVOR0VPbWtCbk8xdDNGTGxKTG1IcHRCSWozQ1BackFRWTZ5UENqeWFxc1ZEUlEzcGNxNmRSaENsY0NxTzJIVGdtOE9EempIdWVzcw?oc=5","date":"2026-01-19","type":"deal","source":"Insilico Medicine","summary":"Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment - Insilico Medicine","headline":"Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant N","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxONGRscGV6TUw0N0NqbEg2d3o2LTM2clJUUTdfcVRHTVVUTEg0YVQtSnZEWUZwY2NFOTN3UDZHSV83eExGYlFMdUdhVmFteUNUWUtQSWFzdG1EVTg5eThzSFh6SGFLTmlIdGU3ZEtCYjlIaHFFNXBHTmJTTlRRQ1dKSg?oc=5","date":"2025-12-03","type":"deal","source":"Labiotech.eu","summary":"Boehringer Ingelheim's pipeline activity: A busy year of dealmaking for the German pharma in 2025 - Labiotech.eu","headline":"Boehringer Ingelheim's pipeline activity: A busy year of dealmaking for the German pharma in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9TXzVFLUxYUjZnQUIzUEVHTWRVbUhtRkNnN2ZscHlyd3JFTEFHeTI3bDU2MlNvSmVlMzNJN3M0RUsxRjJPZG45N18wWWFvZEdWNl8xQXVveFZSWGtJdHgweFRHcERJUTFQakNxRVZaZjBrd3lySjB3S2h2Y0hDZ0k?oc=5","date":"2025-11-26","type":"trial","source":"Clinical Trials Arena","summary":"Enrolment concludes for Inflammasome’s K8 Phase II trial for GA - Clinical Trials Arena","headline":"Enrolment concludes for Inflammasome’s K8 Phase II trial for GA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxPT21YdjAtZ0ZGRDg5R0ZwSFpnZ2wwTVFaYzM1Rlg2NlRFWkg1U0pQalgxWi10QjF6dDhhMzA5N3JNcjVLdWlVdWlUaGlHWGM1MmNDQTdhcUsySVlHS3JuaTd5VkMzMlQ4NFZSM2ZtelBRSzQwZTNLQ2xZSmFXaUtTZ0VLZ2VrRkJucWJGbm12YVdrNURycmJzWnc4SGo1Vkl6b09LMW9oV3NLYUVLMExETHdmSFV2dUQ3NFdYT0FnbDR6THJ4NTlmWGFQcV9TY1JQTWYxRkZFdUhpUUc5ZmJBeEQxUTloUVVzOEl2UDhRYmM0Q3FOZGc0SFE4bERGTVhQRDRSelVLT2pmZnVaNEtqZXlCQnFNYmc1RTcwVkVwMjYwSl82NkpPWFotaF9FQTdNemJVTXhvOHNKUXVCd3FEM0c4Zjlqb0NU?oc=5","date":"2025-11-25","type":"trial","source":"Business Wire","summary":"Inflammasome Therapeutics Completes Enrollment of Multicenter Phase II Dose- Ranging Study for First-in-Class Dual Inflammasome Inhibitor, K8, to Treat Geographic Atrophy - Business Wire","headline":"Inflammasome Therapeutics Completes Enrollment of Multicenter Phase II Dose- Ranging Study for First-in-Class Dual Infla","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxPTjNWREhNMG9UMzB6NmNDYXgyVUhYank5aTNkOEp4eDRReGJGbHZkMS1VVmZiZ0UyTko0eFlUYUdrLUd1U1VNYVdOTm5kTVpsSjdOUGF5LTUyMjlXc2tFZXkxR2J4b09mU0lldjQ0NVREZElsVVJBVHNNcFQ3RjJscWowQ0NGNkg0OWNoMTZlTUhhVWY0VEF1Y0dFVmRFaVVhWlYwRmVsTWhNekRPWWJiUkNNNUJFYTNzQUUwaWJGVGRpN3BXOEJqVlZGdWdvTFpYbWNVaDNucUtxZlIyWlRBaGhDaXJ4UWZnalozckQtTTJQTTVoQWMzS3RCcW9DdVEtcFJBV3V0TGFQYklyYzRyeENEVXhlU0d2YWdBX1N2c0p6MjlZcDAxa1VkdmpIRG50LXNuYw?oc=5","date":"2025-11-13","type":"pipeline","source":"Business Wire","summary":"Shaperon Attends 7th Inflammasome Therapeutics Summit in Boston; CEO Dr. Seungyong Seong Delivers Keynote Presentation on GPCR19-Targeted Drug Development - Business Wire","headline":"Shaperon Attends 7th Inflammasome Therapeutics Summit in Boston; CEO Dr. Seungyong Seong Delivers Keynote Presentation o","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxNa3JseTloMjM2RFJDcWwtZUlPaGo4Y000Z2dSZFhTTEpYeEowNjN0aV94UHNma3c1eW5FREtLM1l1RkZCcWlkMTV1RXVIOENYdmlIcGQ5YnY0VGZiZjdSSXNuZWVYdHpsOS1NbGVVMFpPYlBKbVFtaTNZNUlSRnNUcGsycFJ2V19qbS1RZFR0enM5ZGE3QzN1VFhqU0pPdGJiQkNxZ2JwWllseFRyWG1HRGhzZEs5Zk14eXo2RVNUMUxocUV1enhRRkJNb0J0NU1YcUptQ3BZLVRxVVhJbmpPSHFqbUJJSTZLNkhmYVhybnhoM0lCNld0UzhnLXRRdGlJNHBpcmd2RHpBS2FBYTVuTnZ1dTBmTUZXVU5XOTcwUGlMU3VBcFZYU3V0SFVSQ25MVkptNkQ1LVQ?oc=5","date":"2025-11-10","type":"regulatory","source":"PR Newswire","summary":"Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting - PR Newswire","headline":"Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American So","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxNTVNXR2VFdWxtSUhGd2syTlVDcHNjYVZZNnNKVEs2dTFKa3lPdEVHVzhjT29OYm1aY3VLTllNSTdzZm8xcnhzcXdxcGhGbTY2TE9EMkdYTjgxSzZvWUlWaldXb1hoMmtoR1FYTlBlR0hrWHY4Q1FyQWZFOF9QaTI2eW85WTZLT0JmTnVyYnVsZnpQVFRkTml0UlZVX09NQ29FcVlPRzJXZGFienFCTWJsNU9fUkU4UlliRkZNQU4yN0FTVm9vWGxuX0JBVzcxXzYwZTRqN01iQkRQMlk2WHJEdGJDTE4tVDJkT3pwQXU5dmJ0RFdPZVhweURib2NIMzVHZUJ1VjNreWtGNUc0Y3JxLThHSUhaUWp0MXZtbFkzSEhVVUlPS0JrOQ?oc=5","date":"2025-10-16","type":"trial","source":"globenewswire.com","summary":"Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: - globenewswire.com","headline":"Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOajNVQzFKUGZtQlJSTG00OTZBQ2tZTTVEeUc5YU04T2NPRmx5TjB2OHFJNUhWOGozUVZNSVBxSGFDbU9fTkdzX0IycjhseHlnNWtKZUJDd09aZXluaEd5VFR6OHBoV2x3T3NreU00NVpEV1pMZkducXNzcWNPaFpsaW44VjJsQ2FVci1pTmdR?oc=5","date":"2024-11-13","type":"trial","source":"Yahoo Finance","summary":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - Yahoo Finance","headline":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Th","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1lcWttOEE2eHJVeE9VanBab20zZGpyc0NzbTFzTTZLOVZ6T3ZTdEJrWTk0Q3BXc2JoV0lKYmpiQ2hVZTBjQmZqTWpObHVRdFFpM0hFWklmcVhrSjRHdlNN?oc=5","date":"2023-11-29","type":"pipeline","source":"nature.com","summary":"Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets - nature.com","headline":"Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNMVpYcnNMX0hVZWJvVjBYMWNwb2pyUGVXZXFqbnkzd000TVpvMmlUTmVSbXh1UGZibUM1NzZUZnRkbUJ3RUlXSlZnMkdDdEhVZUo3SUUxenloSnNaQkJRZ1ZjUFI4RllPVVd4eWZmS09rcm5teTFDRldHRG1UenZ6NUtBNjhIQ0Y0dFd1eUhQaEs1R1h4aHJRQW1ZZkViZU5IenNONEpocW96NXc?oc=5","date":"2021-04-11","type":"pipeline","source":"Frontiers","summary":"NLRP3 Inflammasome: A Promising Therapeutic Target for Drug-Induced Toxicity - Frontiers","headline":"NLRP3 Inflammasome: A Promising Therapeutic Target for Drug-Induced Toxicity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQemxCTmozWUliTExBcXdRUlZuZndtZXZVRUhIeVVPOVFUemh0UEktUFpEQXZDSV9xSkFveVJjUjFzcU1CcXBjWmVWRDNBVjY3WnhqMElNd24zX3N0aHhqLVVjWFdwdDNBYkNYel9sc0Jsejg4LWxiMTlFSEozeDFtZ3RjRFF6cWhrVktxdTNmNlpCY3dqeWc?oc=5","date":"2020-09-24","type":"deal","source":"C&EN","summary":"Roche buys Inflazome for $445 million - C&EN","headline":"Roche buys Inflazome for $445 million - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPY3RUWlp4SGxZbzFoUzlkNzJ3R1o2MVAxYnQzQlBQTHdrMGNXbldkUDllU1ZUV01kbkNQT1dYbmk5S3ExVnkzQWkzLVVzX2gtRTJGQVRZNVM0OVZ4bGF3ZmU5YUh6WDdNMGVtUUlXMEliTVNFSWhSVjNLMFZudmlkaVp1VXVibGthSzBiWlVIQ3A?oc=5","date":"2020-09-21","type":"deal","source":"BioPharma Dive","summary":"Roche buys Inflazome as pharma interest in targeting inflammation grows - BioPharma Dive","headline":"Roche buys Inflazome as pharma interest in targeting inflammation grows","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}